The company, which is also markets its REX device for use in physiotherapy, expects to ship four units in the second half compared with three in the first six months of the financial year.
Traction in the States, underlined most recently by interest from the US Army, means the company will direct its limited resources at the world’s largest market.
It will also support the registrations in China where an initial training programme has been concluded.
That said, sales enquiries in other territories will ‘pursued’, Rex added.
Chief executive Crispin Simon told investors: "Most people who see a robotic exoskeleton immediately grasp its value and its potential to transform lives.
“We have delivered commercial sales, clinical evidence and new partnerships, and are especially pleased with the agreement we announced last week with the US Army.
“Our goal is to be the market leader in this exciting new technology.”
In the same announcement, Rex said recruitment for its RAPPER II clinical trial is progressing well.
A total of 31 volunteers have been recruited to date, and two new trial centres, the Royal National Orthopaedic Hospital in Stanmore, UK and Austin Health's Royal Talbot Rehabilitation Centre in Melbourne, Australia.
Robot-Assisted Physiotherapy Exercises with REX (RAPPPER II) is a trial to evaluate the safety and feasibility of a set of customised exercises performed in a REX unit.
The involvement of some of the world's leading neuro-rehabilitation clinics in the process represented a “valuable endorsement” of the technology, the firm said.
WinterGreen Research reckons the market for robotic exoskeletons for medical applications is poised for significant growth, with global sales forecast to reach $2.1bn by 2021.